The side effects were common, including fever and a deterioration in symptoms from rheumatoid arthritis, but occurred only in the first three days after infusion.
"Guidelines recommend prescription of risedronate or alendronate in many patients given glucocorticoids, who are at increased risk of fracture," The Telegraph quoted the study as saying.
It concluded: "However, our study has shown that one intravenous infusion of zoledronic acid provides greater increases in bone mineral density and more rapid and substantial decreases in bone turnover than does daily risedronate."
The researchers called for larger studies to establish whether increasing bone density will cut the rate of fracture.
The study is published in the latest issue of The Lancet.
Source-ANI
TAN